Alpha Teknova, Inc. (TKNO) stock
TKNONasdaqIn Vitro & In Vivo Diagnostic SubstancesFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 5, 2026Score 12/30125% above fair value
$7.77−0.44 (-5.36%)
Close on Nov 16, 2026Market cap $417.16MP/E –Yield –
Alpha Teknova total debt
Total debt is short-term plus long-term borrowings on the balance sheet at the end of each period.
Alpha Teknova's total debt was $0 at Dec 31, 2025. For fiscal 2025 it was $0, down 100.0% from the year before.
Annual total debt
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $0 | -100.0% |
| FY2024 | Dec 31, 2024 | $4.05M | -69.5% |
| FY2023 | Dec 31, 2023 | $13.25M | -39.7% |
| FY2022 | Dec 31, 2022 | $21.98M | – |
Quarterly total debt
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q4 FY2025 | Dec 31, 2025 | $0 | -100.0% |
| Q3 FY2025 | Sep 30, 2025 | $0 | -100.0% |
| Q2 FY2025 | Jun 30, 2025 | $0 | -100.0% |
| Q1 FY2025 | Mar 31, 2025 | $0 | -100.0% |
| Q4 FY2024 | Dec 31, 2024 | $4.05M | -69.5% |
| Q3 FY2024 | Sep 30, 2024 | $13.39M | +1.6% |
| Q2 FY2024 | Jun 30, 2024 | $13.28M | -40.1% |
| Q1 FY2024 | Mar 31, 2024 | $13.18M | -40.0% |
| Q4 FY2023 | Dec 31, 2023 | $13.25M | – |
| Q3 FY2023 | Sep 30, 2023 | $13.17M | – |
| Q2 FY2023 | Jun 30, 2023 | $22.16M | – |
| Q4 FY2022 | Dec 31, 2022 | $21.98M | – |
See a number that looks wrong?